Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.38 |
| ▸ | ANO1 | Q5XXA6 | 6/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6581594 | 0.89 | PTPN1 (0.47) | PTPN1ANO1MAPTTP53RXFP1 | |
| SCHEMBL6582262 | 0.89 | PTPN1 (0.48) | SLC2A1PTPN1ANO1ALOX5MAPT | |
| SCHEMBL6583854 | 0.87 | SLC2A1 (0.49) | SLC2A1ANO1ALOX5KCNH2MAPT | |
| SCHEMBL6586154 | 0.86 | ALOX5 (0.42) | SLC2A1PTPN1ANO1ALOX5MAPT | |
| SCHEMBL6580545 | 0.84 | SLC2A1 (0.37) | SLC2A1PTPN1ANO1ALOX5MAPT | |
| SCHEMBL6579758 | 0.84 | ALOX5 (0.42) | SLC2A1PTPN1ANO1ALOX5MAPT | |
| SCHEMBL6579841 | 0.83 | LMNA (0.40) | SLC2A1PTPN1ANO1MAPTTP53 | |
| SCHEMBL6579600 | 0.80 | LMNA (0.42) | PTPN1ANO1KCNH2MAPTTP53 | |
| SCHEMBL6579760 | 0.79 | LMNA (0.39) | PTPN1ANO1MAPTTP53RXFP1 | |
| SCHEMBL6581487 | 0.77 | PTPN1 (0.58) | PTPN1ANO1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401822-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2003000671-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | F2R, SERPINE1, SERPINC1 | SLC2A1 2299/4885PTPN1 1287/4885ANO1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.